Capital Flow Monitor · Sponsors · CIK 2111460
Lonestar Medicines, Inc.
200 BERKELEY STREET, BOSTON, MA, 02116 · 518-313-0994
Biotechnology · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$45.0M
Sold
$25.0M
% sold
55.6%
Investors
4
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-02-23 | D ·current | 506(b) | $45.0M | $25.0M | 55.6% | 4 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Stephen Basil Thomas — Executive Officer / Director / Promoter, BOSTON, MA
1 other raise
- Memento Medicines, Inc. $38.0M of $93.0M · 40.9%
-
William Daley Bonificio — Executive Officer / Promoter, BOSTON, MA
1 other raise
- Memento Medicines, Inc. $38.0M of $93.0M · 40.9%
-
Naveen Manu Daryani — Executive Officer, BOSTON, MA
1 other raise
- Memento Medicines, Inc. $38.0M of $93.0M · 40.9%
-
Andrew Levin — Director, BOSTON, MA
4 other raises
- Climb Bio, Inc. $110.1M of $110.1M · 100.0%
- Slate Medicines, Inc. $10.0M of $130.0M · 7.7%
- Imbria Pharmaceuticals, Inc. $66.7M of $144.2M · 46.3%
- Pahr Therapeutics, Inc. $4.7M of $14.0M · 33.3%
- Gianna Hoffman-Luca — Director, BOSTON, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.